Addex (ADXN) CMO Roger Mills Reprices Options

What Happened
Roger Mills, Chief Medical Officer and director of Addex Therapeutics (ADXN), was party to a set of option-related adjustments on September 2, 2026. The filing shows paired "disposition to issuer" and "acquisition" entries for 392,837 common shares plus 50,000 derivative units (total 442,837 units). These entries reflect a repricing/adjustment of previously issued/exercised options under the company’s deferred strike price payment plan — the exercise price for all affected units was reduced to $0.032 per share (U.S. dollar amounts reflect conversion from CHF at $1.2296/CHF). The Form 4 reports $0.00 as the transaction price because this filing documents the contractual repricing/administrative adjustment rather than an open-market purchase or sale.

Key Details

• Transaction date: September 2, 2026; Form 4 filed September 4, 2026 (timely within the standard 2-business-day window).
• Reported entries: disposition to issuer (D) and acquisition (A) for 392,837 common shares and D/A for 50,000 derivative units.
• Repriced exercise price: $0.032 per share (USD, conversion from CHF at $1.2296/CHF).
• Exemptions: Transactions reported as exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act.
• Shares owned after transaction: not specified in the supplied extract of the Form 4 — see the filing for the post-transaction beneficial ownership number.
• Footnotes: Confirm these were adjustments to options/shares originally acquired under deferred strike payment arrangements (some units dated Oct 26, 2022 and Nov 27, 2023).

Context
This is not an open-market sale or purchase; it documents an internal repricing/administrative change to option/exercise terms that lowers the strike price. For retail investors, note that repricings make the option holder’s position more valuable if the stock later rises, but the filing alone does not indicate buying or selling in the market or management’s view on the stock. The filing is explanatory and treated as exempt under Rule 16b provisions.